Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health, Hoffmann La RochefiledCriticalUs Health
Publication of AR097922A1publicationCriticalpatent/AR097922A1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Micro-Organisms Or Cultivation Processes Thereof
(AREA)
Abstract
Se provee una exotoxina A de Pseudomonas (PE) que comprende una secuencia de aminoácidos teniendo una sustitución de uno o más epítopos de las células B y/o células T. Se provee además moléculas quiméricas relacionadas, así como también ácidos nucleicos relacionados, vectores de expresión recombinantes, células huésped, poblaciones de células, así como composiciones farmacéuticas. Métodos para el tratamiento o prevención del cáncer en un mamífero, métodos para la inhibición del desarrollo de una célula objetivo, métodos para la producción de la PE y métodos para la producción de la molécula quimérica son adicionalmente provistos.An exotoxin A of Pseudomonas (PE) is provided which comprises an amino acid sequence having a substitution of one or more epitopes of B cells and / or T cells. In addition, related chimeric molecules, as well as related nucleic acids, are provided. recombinant expression, host cells, cell populations, as well as pharmaceutical compositions. Methods for the treatment or prevention of cancer in a mammal, methods for inhibiting the development of a target cell, methods for the production of PE and methods for the production of the chimeric molecule are additionally provided.
ARP140103701A2013-10-062014-10-03
MODIFIED PSEUDOMONAS EXOTOXIN A
AR097922A1
(en)
heterodimeric protein, nucleic acid and expression vector compositions, expression vector, host cell, and methods for producing heterodimeric protein and for treating cancer in a patient
Humanized antibody that binds to human cdcp1 useful in the treatment of cancer; pharmaceutical composition; nucleic acid, expression vector and host cell comprising it; and method of producing the antibody.
Isolated antibody, derivatives or isolated fragments thereof capable of binding to the cd151 protein, composition comprising it; nucleic acid encoding it, vector and host cell comprising it; procedure for preparing said antibody; Useful as a medicine to prevent or treat cancer.